Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 5 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Treatment Outcome and Author is Boland, Brigid S  [Clear All Filters]
2021
Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Casteele NVande et al..  2021.  Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis.. Clin Gastroenterol Hepatol. 19(3):511-518.e6.
2020
Yang E, Panaccione N, Whitmire N, Dulai PS, Casteele NVande, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R et al..  2020.  Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.. Aliment Pharmacol Ther. 51(11):1031-1038.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al..  2020.  Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.
2018
Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al..  2018.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..  2018.  Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.